Written by: Alyson Leonard, PharmD, BCPS, BCOP Cone Health Download Here Description: Cabazitaxel is indicated for treatment of patients with metastatic castration-resistant prostate (mCRPC) cancer previously treated with a docetaxel-containing treatment regimen in combination with prednisone.1 The purpose of this PQI is to provide guidance for initiating cabazitaxel. Background: Cabazitaxel was FDA approved in 2010 […]

Written by: Jeff Engle, PharmD, MS Download Here Description: This PQI will discuss effective management of adverse effects of sorafenib in the treatment of hepatocellular carcinoma and discuss data supporting the sequencing of patients to second-line therapy with regorafenib for increased survival benefit.   Background: Hepatocellular carcinoma (HCC) is associated with a high mortality rate […]

Written by: Derek Gyori, PharmD and Julianne Orr, PharmD Download Here Description: Abemaciclib is FDA-approved in combination with an aromatase inhibitor, fulvestrant, and as a single agent in early high-risk, advanced, or metastatic breast cancer. This PQI will address effective practices for the management of abemaciclib associated diarrhea, a common toxicity with this therapy. Background: Abemaciclib […]

Written by: Jan Montgomery, PharmD, South Carolina Oncology Associates and Jacob Dygert, South University School of Pharmacy Download Here Description: To identify appropriate eligible patients for abemaciclib therapy based upon specific prognostic factors. Background: Abemaciclib is indicated for the treatment of postmenopausal women with HR-Positive, HER2- Negative in early high-risk, advanced, or metastatic breast cancer. […]

  Media Contacts: Jenine Anderson│Public Relations Manager Jenine.Anderson@primetherapeutics.com Suzi Baugh│850-545-4247 Suzi@sachsmedia.com     Going beyond the first fill: Prime Therapeutics, NCODA collaboration enables improved patient outcomes through new oncology pharmacy accreditation Accredited medically integrated pharmacies may become eligible to participate in Prime’s IntegratedRx™ – Oncology network EAGAN, Minn. and CAZENOVIA, NY– Oct. 19, 2021 – […]

FOR IMMEDIATE RELEASE MEDIA CONTACT: October 18, 2021 Suzi Baugh Suzi@sachsmedia.com 850-545-4247 A Win For Cancer Patients: First-of-Its-Kind Collaboration Between National Oncology Pharmacy Nonprofit and PBM NCODA’s medically integrated pharmacy accreditation creates gold standard for oncology practices dispensing medication to patients, from first to last fill CAZENOVIA, NY – NCODA, an organization dedicated to providing […]

Written by: Prithviraj Bose, MD, UT MD Anderson Cancer Center DOWNLOAD HERE Description: The purpose of this PQI is to assist in the diagnosis of the advanced systemic mastocytosis patient by providing a diagnostic algorithm. Background: Systemic mastocytosis (SM) is a myeloid neoplasm driven in ~95% of cases by an activating mutation, D816V, affecting exon […]

Written By: Joshua Nubla, PharmD, NCODA Download Here Description: This PQI is developed to provide guidance for management of patients treated with selpercatinib. Background: Selpercatinib is a kinase inhibitor indicated for the treatment of: Adult patients with metastatic RETfusion-positive non-small cell lung cancer (NSCLC) Adult and pediatric patients 12 years of age and older with advanced […]

Written by Isabel Houlzet, PharmD, BCPS, BCOP, Miami Cancer Institute Download Here Description: This PQI will review patient identification and clinical considerations for this treatment option for gastric cancer. Background: Trifluridine and Tipiracil is approved for use in patients with gastric or gastroesophageal junction (GEJ) cancer who have failed at least two prior lines of […]

Written By: Joshua Nubla, PharmD, NCODA Download Here Description: The purpose of this PQI is to discuss the option of using bortezomib for multiple myeloma (MM) and mantle cell lymphoma (MCL) patients. Background: Bortezomib is a reversible proteasome inhibitor of the chymotrypsin-like activity of the 26S proteasome and is approved for treatment of adult patients […]

Written by: Jody Agena, PharmD, Virginia Cancer Specialists Download Here Description: Understand how to identify eligible patients and manage adverse effects of regorafenib treatment in hepatocellular carcinoma. Background: Regorafenib is a kinase inhibitor indicated for the treatment of patients (Childs Pugh A) with Hepatocellular Carcinoma (HCC) who have been previously treated with sorafenib.  In the […]

Written by: Michelle Phillips, PharmD, University of Rochester Medical Center Download Here Description: The purpose of this PQI is to highlight key criteria for appropriate monitoring, dosing, and administration to improve the dispensing and management of patients taking niraparib (Zejula). Background: Niraparib is indicated for the maintenance treatment of patients with recurrent epithelial ovarian, fallopian […]